Clinical and biological characteristics in the 3 patient groups
| . | HLH group (n = 68) . | DC group (n = 34) . | HC group (n = 34) . | P* . |
|---|---|---|---|---|
| General data | ||||
| Median age (min-max), y | 58 (28-91) | 56 (25-81) | 51 (37-76) | .4 |
| Female sex, n (%) | 34 (50) | 16 (47) | 17 (50) | — |
| Disease, n | ||||
| Lymphoma† | 18 | 8 | — | .8 |
| SLE | 7 | 6 | — | .3 |
| AOSD | 3 | 6 | — | .04 |
| Bacterial,‡ parasite§ | 28 | 14 | — | .9 |
| Virus (EBV, CMV) | 2 | 0 | — | .5 |
| Idiopathic | 10 | 0 | — | .01 |
| Clinical, % | ||||
| Fever | 91 | 59 | — | <.001 |
| Tumoral syndrome‖ | 59 | 35 | — | .02 |
| Biology, median (min-max) | ||||
| Hemoglobin, g/dL | 9 (7.4-12) | 11.6 (8.7-14.6) | — | <.001 |
| Platelets, ×109/L | 74 (15-176) | 258 (114-481) | — | <.001 |
| Neutrophils, ×109/L | 1.3 (0-8) | 3.5 (1.5-17) | — | <.001 |
| Fibrinogen, g/L | 3.3 (1.4-6.4) | 3.8 (2.2-7.1) | — | .07 |
| Ferritin, ng/mL | 3100 (951-27 752) | 882 (53-9542) | — | <.001 |
| Triglycerides, g/L | 2.5 (1.3-4.9) | 1.5 (0.6-2.9) | — | <.001 |
| sCD25, pg/mL | 8045 (1819-43 601) | 4051 (1711-11 800) | 999 (534-1654) | .002 |
| BM hemophagocytosis, % | 91 | — | — | — |
| . | HLH group (n = 68) . | DC group (n = 34) . | HC group (n = 34) . | P* . |
|---|---|---|---|---|
| General data | ||||
| Median age (min-max), y | 58 (28-91) | 56 (25-81) | 51 (37-76) | .4 |
| Female sex, n (%) | 34 (50) | 16 (47) | 17 (50) | — |
| Disease, n | ||||
| Lymphoma† | 18 | 8 | — | .8 |
| SLE | 7 | 6 | — | .3 |
| AOSD | 3 | 6 | — | .04 |
| Bacterial,‡ parasite§ | 28 | 14 | — | .9 |
| Virus (EBV, CMV) | 2 | 0 | — | .5 |
| Idiopathic | 10 | 0 | — | .01 |
| Clinical, % | ||||
| Fever | 91 | 59 | — | <.001 |
| Tumoral syndrome‖ | 59 | 35 | — | .02 |
| Biology, median (min-max) | ||||
| Hemoglobin, g/dL | 9 (7.4-12) | 11.6 (8.7-14.6) | — | <.001 |
| Platelets, ×109/L | 74 (15-176) | 258 (114-481) | — | <.001 |
| Neutrophils, ×109/L | 1.3 (0-8) | 3.5 (1.5-17) | — | <.001 |
| Fibrinogen, g/L | 3.3 (1.4-6.4) | 3.8 (2.2-7.1) | — | .07 |
| Ferritin, ng/mL | 3100 (951-27 752) | 882 (53-9542) | — | <.001 |
| Triglycerides, g/L | 2.5 (1.3-4.9) | 1.5 (0.6-2.9) | — | <.001 |
| sCD25, pg/mL | 8045 (1819-43 601) | 4051 (1711-11 800) | 999 (534-1654) | .002 |
| BM hemophagocytosis, % | 91 | — | — | — |
BM, bone marrow; CMV, cytomegalovirus; EBV, Epstein-Barr virus; min-max, minimum-maximum; SLE, systemic lupus erythematosus.
Mann-Whitney U test (2 groups) and Kruskal-Wallis test (3 groups) for continuous data; χ2 square test for categorical variables.
∞B-cell lymphoma: 16 of 18 in HLH patients and 6 of 8 in DCs; T-cell lymphoma: 2 of 18 in HLH patients and 2 of 8 in DCs.
Bacterial infections: 23 of 28 HLH patients (including 3 with mycobacteria) and 12 of 14 DCs.
Parasites: 5 of 28 HLH patients (4 with leishmaniosis, 1 with babesiosis) and 2 of 14 DCs (2 with leishmaniosis).
Tumoral syndrome: lymphadenopathy, splenomegaly, and/or hepatomegaly.